Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Furuse

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
ESMO Open|October 1, 2024
Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)M Ueno, C Morizane, M Ikeda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialM Ikeda, S Shimizu, T Sato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et alM Ikeda, S Shimizu, T Sato, et al.
Investigational New Drugs|December 16, 2014
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancerMasato Matsuyama, H Ishii, J Furuse, et al.
The Pharmacogenomics Journal|December 24, 2008
A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studiesY Sato, N M Laird, K Nagashima, et al.
International Journal of Clinical Practice|November 29, 2013
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisR Lencioni, M Kudo, S-L Ye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerM Ueno, T Okusaka, Y Omuro, et al.
British Journal of Cancer|January 13, 2017
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerT Ioka, Y Komatsu, N Mizuno, et al.
International Journal of Clinical Practice|June 16, 2012
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional studyR Lencioni, M Kudo, S-L Ye, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
ESMO Open|October 1, 2024
Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)M Ueno, C Morizane, M Ikeda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2018
REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patientsK Shitara, T Yamanaka, T Denda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2016
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialM Ikeda, S Shimizu, T Sato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 2017
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et alM Ikeda, S Shimizu, T Sato, et al.
Investigational New Drugs|December 16, 2014
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancerMasato Matsuyama, H Ishii, J Furuse, et al.
The Pharmacogenomics Journal|December 24, 2008
A new statistical screening approach for finding pharmacokinetics-related genes in genome-wide studiesY Sato, N M Laird, K Nagashima, et al.
International Journal of Clinical Practice|November 29, 2013
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysisR Lencioni, M Kudo, S-L Ye, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2015
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancerM Ueno, T Okusaka, Y Omuro, et al.
British Journal of Cancer|January 13, 2017
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancerT Ioka, Y Komatsu, N Mizuno, et al.
International Journal of Clinical Practice|June 16, 2012
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional studyR Lencioni, M Kudo, S-L Ye, et al.
Pageof 6